Pro-Dex (PDEX) Stock Forecast, Price & News

Pro-Dex's stock was trading at $15.90 at the start of the year. Since then, PDEX stock has increased by 19.4% and is now trading at $18.99.
View the best growth stocks for 2023 here.

Pro-Dex saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 11,300 shares, an increase of 18.9% from the April 30th total of 9,500 shares. Based on an average trading volume of 4,400 shares, the days-to-cover ratio is currently 2.6 days. Currently, 0.5% of the company's shares are short sold.
View Pro-Dex's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023.
View our PDEX earnings forecast.

Pro-Dex, Inc. (NASDAQ:PDEX) issued its earnings results on Monday, November, 15th. The medical instruments supplier reported $0.28 earnings per share for the quarter, meeting the consensus estimate of $0.28. The medical instruments supplier earned $9.99 million during the quarter. Pro-Dex had a net margin of 9.72% and a trailing twelve-month return on equity of 19.00%.

3 employees have rated Pro-Dex Chief Executive Officer Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH).

Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."

Pro-Dex's stock is owned by many different institutional and retail investors. Top institutional shareholders include Punch & Associates Investment Management Inc. (1.78%), Dimensional Fund Advisors LP (1.62%), LSV Asset Management (0.89%) and UBS Group AG (0.17%). Insiders that own company stock include Alisha Charlton, Katrina Marie Kramer Philp, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III.
View institutional ownership trends.

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PDEX stock can currently be purchased for approximately $18.99.

Pro-Dex (NASDAQ:PDEX) has a market capitalization of $67.32 million and generates $48.06 million in revenue each year. The medical instruments supplier earns $3.86 million in net income (profit) each year or $1.27 on an earnings per share basis.

The company employs 117 workers across the globe.

Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The official website for the company is www.pro-dex.com. The medical instruments supplier can be reached via phone at (949) 769-3200, via email at investor.relations@pro-dex.com, or via fax at 949-769-3281.